Compare MRAM & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | ENTA |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.8M | 374.6M |
| IPO Year | 2016 | 2012 |
| Metric | MRAM | ENTA |
|---|---|---|
| Price | $32.29 | $13.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $18.50 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 5.8M | 178.7K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | $49,417,000.00 | ★ $102,814,000.00 |
| Revenue This Year | $10.22 | $7.76 |
| Revenue Next Year | $7.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.51 | 16.48 |
| 52 Week Low | $5.49 | $5.78 |
| 52 Week High | $51.50 | $17.15 |
| Indicator | MRAM | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 59.11 | 44.79 |
| Support Level | $8.48 | $13.19 |
| Resistance Level | $51.50 | $13.76 |
| Average True Range (ATR) | 5.91 | 0.81 |
| MACD | -0.59 | -0.11 |
| Stochastic Oscillator | 41.27 | 13.87 |
Everspin Technologies Inc is a manufacturer of Magnetoresistive Random Access Memory (MRAM) technology. The company manufactures MRAM products using both captive and third-party manufacturing capabilities. It purchases industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes magnetic-bit technology at leased 200mm fabrication facility in Chandler, Arizona. It also manufactures full-flow 300mm CMOS wafers with STT-MRAM magnetic-bit technology integrated in BEOL. The company's customers are in key markets, such as industrial, medical, automotive/transportation, aerospace, and data center.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.